Of the 26 companies that make up the Genome Technology Index, fully half were not public a year ago. At our editorial closing another dozen genome technology IPOs were in the pipeline.
We think an industry this dynamic deserves its own benchmark. So we’ve created one.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
